Search Results - "ONDEYKA, D. L"

In vivo pharmacology of L-158,809, a new highly potent and selective nonpeptide angiotensin II receptor antagonist by Siegl, P K, Chang, R S, Mantlo, N B, Chakravarty, P K, Ondeyka, D L, Greenlee, W J, Patchett, A A, Sweet, C S, Lotti, V J

“…L-158,809 (5,7-dimethyl-2-ethyl-3-[[2'-(1H-tetrazol-5yl)[1,1']-bi- phenyl-4-yl]-methyl]-3H-imidazo[4,5-b]pyridine) is a potent, competitive and specific…”
Get more information

Potent, orally active imidazo[4,5-b]pyridine-based angiotensin II receptor antagonists by Mantlo, Nathan B, Chakravarty, Prasun K, Ondeyka, Debra L, Siegl, Peter K. S, Chang, Raymond S, Lotti, Victor J, Faust, Kristie A, Schorn, Terry W, Chen, Tsing Bau

Get full text

A new class of angiotensin-converting enzyme inhibitors by Patchett, A. A, Harris, E, Tristram, E. W, Wyvratt, M. J, Wu, M. T, Taub, D, Peterson, E. R, Ikeler, T. J, ten Broeke, J, Payne, L. G, Ondeyka, D. L, Thorsett, E. D, Greenlee, W. J, Lohr, N. S, Hoffsommer, R. D, Joshua, H, Ruyle, W. V, Rothrock, J. W, Aster, S. D, Maycock, A. L, Robinson, F. M, Hirschmann, R, Sweet, C. S, Ulm, E. H, Gross, D. M, Vassil, T. C, Stone, C. A

“…Much current attention focuses on the renin-angiotensin system in relation to mechanisms controlling blood pressure and renal function. Recent demonstrations…”
Get full text

Design of a selective insulin receptor tyrosine kinase inhibitor and its effect on glucose uptake and metabolism in intact cells by Saperstein, Richard, Vicario, Pasquale P, Strout, H. Vincent, Brady, Edward, Slater, Eve E, Greenlee, William J, Ondeyka, Debra L, Patchett, Arthur A, Hangauer, David G

“…An inhibitor of the insulin receptor tyrosine kinase (IRTK), (hydroxy-2-naphthalenyl-methyl) phosphonic acid, was designed and synthesized and was shown to be…”
Get full text

Synthesis of N2-[(S)-1-carboxy-3-phenylpropyl]-L-lysyl-L-proline (lisinopril) by Wu, M T, Douglas, A W, Ondeyka, D L, Payne, L G, Ikeler, T J, Joshua, H, Patchett, A A

“…The synthesis and some of the spectral properties of N2-[(S)-1-carboxy-3-phenylpropyl]-L-lysyl-L-proline (lisinopril, MK-521) are described. This compound…”
Get more information

Effects of subtype-selective and balanced angiotensin II receptor antagonists in a porcine coronary artery model of vascular restenosis by HUCKLE, W. R, DRAG, M. D, MANTLO, N. B, CHANG, R. S. L, REILLY, C. F, SCHWARTZ, R. S, GREENLEE, W. J, JOHNSON, R. G, ACKER, W. R, POWERS, M, MCFALL, R. C, HOLDER, D. J, FUJITA, T, STABILITO, I. I, DOOSEOP KIM, ONDEYKA, D. L

“…Numerous studies have demonstrated the ability of angiotensin II (Ang II) receptor antagonists and angiotensin-converting enzyme (ACE) inhibitors to inhibit…”
Get full text

AT1/AT2-BALANCED ANGIOTENSIN II ANTAGONISTS by Ashton, Wallace T., Chang, Linda L., Flanagan, Kelly L., Mantlo, Nathan B., Ondeyka, Debra L., Kim, Dooseop, de Laszlo, Stephen E., Glinka, Tomasz W., Rivero, Ralph A., Kevin, Nancy J., Chang, Raymond S.L., Siegl, Peter K.S., Kivlighn, Salah D., Greenlee, William J.

“…Three heterocyclic series of nonpeptide angiotensin II receptor antagonists (quinazolinones, imidazo[4,5-b]pyridines, and triazolinones) have been transformed…”
Get full text

In vivo pharmacology of an angiotensin AT1 receptor antagonist with balanced affinity for angiotensin AT2 receptors by KIVLIGHN, S. D, ZINGARO, G. J, GABEL, R. A, BROTEN, T. P, CHANG, R. S. L, ONDEYKA, D. L, MANTLO, N. B, GIBSON, R. E, GRENLEE, W. J, SIEGL, P. K. S

Get full text

In vivo pharmacology of an angiotensin AT1 receptor antagonist with balanced affinity for AT2 receptors by Kivlighn, S D, Zingaro, G J, Gabel, R A, Broten, T P, Chang, R S, Ondeyka, D L, Mantlo, N B, Gibson, R E, Greenlee, W J, Siegl, P K

“…L-163,017 (6-[benzoylamino]-7-methyl-2-propyl-3-[[2'-(N-(3-methyl-1-butoxy) carbonylaminosulfonyl)[1,1']-biphenyl-4-yl]methyl]-3H-imidazo[4,5- b]pyridine) is a…”
Get full text